Purple Biotech Ltd., a publicly traded corporation based in Israel, has announced a strategic collaboration with Converge Bio aimed at expediting the development of its innovative tri-specific antibody platform through artificial intelligence (AI) integration.
This partnership, reported on 25 March 2026, is expected to leverage advanced AI technologies to streamline research processes and enhance the efficiency of antibody development. Tri-specific antibodies represent a significant advancement in therapeutic capabilities, with potential applications in targeted disease treatment.
Purple Biotech, previously known under several names including Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd., continues to operate from its headquarters at Oppenheimer Science Park in Rehovot, Israel. The company has a history of focusing on innovative biopharmaceutical solutions, and this collaboration signifies its ongoing commitment to integrating cutting-edge technology in its research practices.
The collaboration with Converge Bio is anticipated to facilitate the optimisation of the tri-specific antibody platform, allowing for more rapid advancements in clinical applications. By utilising AI, the companies aim to enhance the precision and effectiveness of antibody design and production.
For stakeholders interested in the advancements of biotechnologies, this partnership highlights the growing trend of incorporating AI into research and development. As the industry evolves, such collaborations are essential in fostering innovation that aligns with ethical considerations and sustainable practices.
For additional insights into funding opportunities relevant to biotechnology research, stakeholders can explore resources provided by various funding organisations and initiatives dedicated to promoting responsible research and innovation.
For more information, stakeholders can contact Purple Biotech directly at:
- Telephone: 03-9333121
- Fax: 03-5097196
- Email: ir@purple-biotech.com
- Website: www.kitovpharma.com
This announcement underscores Purple Biotech’s ongoing efforts to remain at the forefront of biopharmaceutical innovation while ensuring ethical and responsible practices in research and development.